Molecular Partners, Orano Med dose first patients in MP0712 DLL3 radio-DARPin Phase 1/2a trial

Molecular Partners AG Sponsored ADR

Molecular Partners AG Sponsored ADR

MOLN

0.00
  • Molecular Partners reported first patients dosed in a US Phase 1/2a trial of DLL3-targeting 212Pb Radio-DARPin MP0712.
  • Program is partnered with Orano Med; initial data expected in 2026, with broader safety and efficacy results targeted for 2027.
  • Trial uses 203Pb imaging and dosimetry before treatment; patients can receive up to four 212Pb doses across up to four dose levels.
  • Five US sites are recruiting; the first patient has moved into repeat dosing, with cohort 1 recruited.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Molecular Partners AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607020100OMX_____CNEWS_EN_GNW9755976_en) on July 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.